Industry Roundup: J&J Supreme Court Petition, Ostroff Talks Supplement Regulation
This article was originally published in The Tan Sheet
Supreme Court denies J&J petition in Motrin litigation; FDA chews on latest spiked supplement finding; Ostroff touts supplement market regulation; and more news in brief.
You may also be interested in...
Johnson & Johnson files a writ of certiorari asking the Supreme Court to review a $140m judgment against the firm in Massachusetts. Questions over “clear evidence” needed for FDA decision to pre-empt state courts are at heart of issue and need the court’s consideration.
Vertex and partner CRISPR Therapeutics hope CDX001 can offer a single-use curative regimen for sickle cell disease and beta thalassemia patients. A regulatory filing is possible within 18-24 months.
Worldwide consumer health sales in January-March period were down 3.3% to $3.5bn with results off 7.4% to $1.6bn in the US and up 0.5% to $1.9bn internationally. However, excluding “COVID-19 comparison” in the year-ago period, the consumer health segment grew low-single-digits.